Lupus & antiphospholipid syndrome
Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study
Authors' conclusion
First-trimester exposure to HCQ was not associated with a significantly increased risk of MCM.
Study context
- Population
- All singleton births (2006–2021) among individuals with prevalent systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in SwedenSLE 1007 births
- Exposure
- First-trimester hydroxychloroquine (HCQ) exposure vs no exposure
- SLE exposedn = 453
- RA exposedn = 144
- Outcome
- Infant MCM within 1 year of birth
- Follow-up
- 1 year of birth
Methodological detailsSwedish nationwide registers, inverse probability of treatment weighting, modified Poisson regression with robust variance
- Swedish nationwide registers
- Inverse probability of treatment weighting
- Modified Poisson regression with robust variance
Main finding
As reported in the abstract
Adjusted risk difference
0.9%
SLE exposed vs SLE unexposed · SLE
Adjusted risk difference
1.3%
RA exposed vs RA unexposed · RA
Observational data: associations, not effects.
Further findings
Major congenital malformations (MCM), pooled analysis (exposed vs unexposed)
- Adjusted RR
- 1.30 (95% CI 0.76, 2.23)
Sensitivity analyses (different exposure and outcome windows)
- Yielded similar findings
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study. Rheumatology (Oxford). Published 13 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →